News
Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.
2018
-
Dec 27, 2018
Chugai Obtains Approval for Genomic Mutation Analysis Program “FoundationOne® CDx Cancer Genomic Profile”
-- Japan’s first program with two functions of cancer genomic profiling and companion diagnostics --
-- Toward the realization of treatment proposal based on patient’s cancer genomic profile -- [PDF 79KB] -
Dec 21, 2018
Chugai’s HEMLIBRA® Subcutaneous Injection Receives Approval for Hemophilia A without Inhibitors and Extension of Dosing Interval
-- HEMLIBRA is now available for Hemophilia A, regardless of inhibitor status -- [PDF 128KB] -
Dec 21, 2018
Chugai Obtains Approval for Anti-PD-L1 Antibody, “TECENTRIQ®” for Additional Dosing of the Treatment of Unresectable, Advanced or Recurrent Non-small Cell Lung Cancer
[PDF 106KB] -
Dec 21, 2018
Chugai Files for Additional Indication and Additional Formulation of Anti-PD-L1 Antibody TECENTRIQ® for Breast Cancer
[PDF 132KB] -
Dec 19, 2018
Chugai’s Satralizumab Meets Primary Endpoint in Phase III Monotherapy Study in NMOSD
- Satralizumab monotherapy significantly reduced risk of relapse - [PDF 178KB] -
Dec 19, 2018
Chugai’s Satralizumab Receives FDA Breakthrough Therapy Designation for Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders
- Designation is Seventh for Chugai Originated Drug - [PDF 137KB] -
Dec 19, 2018
Chugai Files a New Drug Application for a ROS1/TRK Inhibitor Entrectinib for the Treatment of NTRK Fusion-Positive Solid Tumors
[PDF 109KB] -
Dec 10, 2018
Establishment of "Gan with," an Information Website for Cancer Patients, Their Families and Coworkers
[PDF 175KB] -
Dec 07, 2018
Chugai Files for Additional Indication of Anti-PD-L1 Antibody TECENTRIQ® for Small Cell Lung Cancer
[PDF 55KB] -
Dec 06, 2018
Chugai Presents Interim Analysis Data of Phase I/II Study of SKY59, anti-C5 antibody in PNH at ASH
-- SKY59 shows tolerability and efficacy in patient subjects -- [PDF 134KB] -
Dec 06, 2018
Chugai Receives Orphan Drug Designation for TECENTRIQ® in Small cell Lung Cancer and for Entrectinib in NTRK Fusion-positive Solid Tumors
[PDF 124KB] -
Dec 05, 2018
Chugai Files Lawsuit against Alexion for Infringement of its Proprietary Antibody Engineering Technology in Japan
[PDF 90KB] -
Dec 04, 2018
Chugai’s HEMLIBRA® Approved in Taiwan for the Treatment of Hemophilia A with Factor VIII Inhibitors
[PDF 112KB] -
Dec 04, 2018
Results Presented from Primary Analysis of the Phase III HAVEN 2 Study with Chugai’s HEMLIBRA® for Children with Hemophilia A with Inhibitors at the American Society of Hematology 2018
[PDF 195KB] -
Nov 21, 2018
Organizational and Personnel Changes
[PDF 120KB] -
Nov 16, 2018
Chugai Files Lawsuit against Alexion for Infringement of its Proprietary Antibody Engineering Technology in the U.S.
[PDF 19KB] -
Oct 31, 2018
Withdrawal of Lawsuits and Petitions for Provisional Disposition Order
[PDF 97KB] -
Oct 31, 2018
Galderma Announces the Results of Phase 2b Study of Nemolizumab in Patients with Atopic Dermatitis
[PDF 101KB] -
Oct 18, 2018
A First Approach in the Pharmaceutical Industry Starting the Provision of a Treatment Support App for Immune Checkpoint Inhibitor Using Multidisciplinary SNS
- Providing a New Solution for Side Effect Management - [PDF 364KB] -
Oct 18, 2018
Xeloda® Adherence Support App Contributes to Improving Communication between Cancer Patients and Healthcare Providers
[PDF 1.9MB] -
Oct 17, 2018
F. Hoffmann-La Roche Announces Third Quarter Sales 2018
[PDF 65KB] -
Oct 15, 2018
Chugai Presents Results from Phase III Study of Satralizumab in NMOSD at ECTRIMS 2018
- Satralizumab added to baseline therapy significantly reduced risk of relapse - [PDF 192KB] -
Oct 15, 2018
Chugai Expresses its Support for the “Japan Climate Action Summit Declaration”
[PDF 105KB] -
Oct 12, 2018
Filing of Lawsuit on Patent Infringement Concerning Herceptin® Injection, and a Petition for Provisional Disposition Order (2)
[PDF 100KB] -
Oct 12, 2018
Filing of Lawsuit on Patent Infringement Concerning Herceptin® Injection, and a Petition for Provisional Disposition Order (1)
[PDF 100KB] -
Oct 12, 2018
Chugai Releases Disease Awareness Anime about Rheumatoid Arthritis in Multiple Languages Emphasizing Importance of Early Detection/Treatment and Care by Specialists
-- Starring Comedienne Kayoko Ohkubo and Voice Actress Ayana Taketatsu -- [PDF 361KB] -
Oct 10, 2018
Anti-Cancer Agent “PERJETA®,” Approved for Additional Indication of “Neoadjuvant and Adjuvant Therapy for HER2-Positive Early Breast Cancer”
[PDF 110KB] -
Oct 05, 2018
Chugai’s HEMLIBRA® Receives Regulatory Approval from U.S. FDA for Hemophilia A without Inhibitors
[PDF 115KB] -
Oct 01, 2018
Chugai Redesigns Corporate Website
[PDF 416KB] -
Sep 27, 2018
Chugai Sponsors “2018 Wheelchair Softball Tournament in Tokyo”
-- the World Champion U.S. National Team Participates in One of the Largest International Wheelchair Softball Tournaments in Japan-- [PDF 124KB] -
Sep 27, 2018
Chugai and Lilly Enter into a License Agreement for Oral GLP-1 Agonist, OWL833
[PDF 110KB] -
Sep 21, 2018
Contribution of Para-transit Vehicles to Welfare Services
[PDF 264KB] -
Sep 20, 2018
Announcement Regarding the Order to Dismiss in a Lawsuit against Chugai in the U.S.
[PDF 23KB] -
Sep 14, 2018
Chugai Selected for the Fourth Time for Dow Jones Sustainability Asia Pacific Index
[PDF 133KB] -
Sep 14, 2018
Organizational and Personnel Changes
[PDF 224KB] -
Aug 30, 2018
Results of Global Phase III Study with Chugai's HEMLIBRA® for Hemophilia A without Inhibitors Published in the New England Journal of Medicine
[PDF 159KB] -
Aug 29, 2018
Launch of the Anti-Cancer Agent / a Humanized Anti-CD20 Monoclonal Antibody "GAZYVA®"
[PDF 67KB] -
Aug 29, 2018
Chugai Obtains “Platinum Kurumin” Certification from the Minister of Health, Labour and Welfare as a Company Supporting Childrearing
-- Seven Times More Male Employees Took Childcare Leave in Two Years -- [PDF 276KB] -
Aug 03, 2018
Anti-CD20 Monoclonal Antibody “RITUXAN®,”
Application for Approval of Additional Indication of
CD20-Positive Chronic Lymphocytic Leukemia
[PDF 67KB] -
Jul 26, 2018
Announcement of Business Expansion of
Chugai Pharmabody Research Pte. Ltd., Chugai’s Research Subsidiary
[PDF 161KB] -
Jul 26, 2018
Organizational and Personnel Changes
[PDF 232KB] -
Jul 26, 2018
Chugai Enters into Comprehensive Partnership Agreement with Preferred Networks
[PDF 74KB] -
Jul 26, 2018
Construction of a New Synthetic Research Building to Enhance Process Development for Small and Middle Molecule APls
[PDF 104KB] -
Jul 26, 2018
F. Hoffmann-La Roche Announces Half Year Results 2018
[PDF 69KB] -
Jul 17, 2018
Chugai to In-license ROS1/TRK Inhibitor Entrectinib
[PDF 113KB] -
Jul 17, 2018
Relief Efforts Support for the Heavy Rain in Western Japan
[PDF 99KB] -
Jul 02, 2018
Humanized Anti-CD20 Monoclonal Antibody, “GAZYVA® Intravenous Infusion 1000 mg,” Approved for the Treatment of CD20-Positive Follicular Lymphoma
[PDF 59KB] -
Jun 29, 2018
Announcement of an Appeal against Chugai in Patent Infringement Lawsuit
[PDF 23KB] -
Jun 05, 2018
Chugai’s HEMLIBRA® Receives Priority Review Status from U.S. FDA for Hemophilia A without Inhibitors
- Second Designation following Hemophilia A with inhibitors - [PDF 139KB] -
May 29, 2018
Humanized Anti-Human IL-6 Receptor Monoclonal Antibody “ACTEMRA®,”
Application for Approval of Additional Indication of Cytokine Release Syndrome Induced by Treatment with CAR-T Cell Therapy
[PDF 62KB] -
May 24, 2018
Humanized Anti-Human IL-6 Receptor Monoclonal Antibody “ACTEMRA®,” Application for Approval of Additional Indication of Adult Onset Still's Disease
[PDF 56KB] -
May 22, 2018
Launch of HEMLIBRA® Subcutaneous Injection for the Treatment of Hemophilia A
[PDF 159KB] -
May 21, 2018
Chugai Presents Results of Two Pivotal Phase III Studies
for its Bispecific Antibody HEMLIBRA® at WFH 2018
[PDF 220KB] -
May 16, 2018
Chugai’s ALK Inhibitor “Alecensa®” Approved for the Treatment of First Line Therapy on ALK-Positive Non-Small Cell Lung Cancer in Taiwan
[PDF 249KB] -
May 10, 2018
Chugai’s Anti-IL-31 Receptor A Humanized Monoclonal Antibody “nemolizumab,” Long Term Data from Global Phase II Study Published in Journal of Allergy and Clinical Immunology Online
[PDF 112KB] -
Apr 26, 2018
Chugai Files Applications for HEMLIBRA® for the Treatment of Hemophilia A without Factor VIII Inhibitors and for Extension of Dosing Interval
[PDF 67KB] -
Apr 26, 2018
F. Hoffmann-La Roche Announces First Quarter Sales 2018
[PDF 24KB] -
Apr 24, 2018
Organizational and Personnel Changes
[PDF 220KB] -
Apr 20, 2018
Notice of Completion of Disposal of Treasury Shares as Restricted Stock Compensation Plan
[PDF 120KB] -
Apr 18, 2018
Launch of the Anti-Cancer Agent / a Humanized Anti-PD-L1 Monoclonal Antibody “TECENTRIQ®”
[PDF 97KB] -
Apr 17, 2018
Chugai’s HEMLIBRA® Receives Breakthrough Therapy Designation
from U.S. FDA for Hemophilia A without Factor VIII Inhibitors
-The Sixth Designation for Chugai Originated Drug- [PDF 203KB] -
Apr 11, 2018
Waiver of Claims in Patent Infringement Lawsuit
[PDF 23KB] -
Mar 28, 2018
Favorable Ruling in Patent Infringement Lawsuit Relating to Emicizumab
[PDF 22KB] -
Mar 23, 2018
Anti-Coagulation Factor IXa/X Humanized Bispecific Monoclonal Antibody HEMLIBRA® Subcutaneous Injection Approved in Japan
[PDF 74KB] -
Mar 23, 2018
Notice of Disposal of Treasury Shares as Restricted Stock Compensation Plan
[PDF 112KB] -
Mar 22, 2018
Chugai Selected as a “Nadeshiko Brand” for the Fourth Consecutive Year and also Recognized in the “New Diversity Management Selection 100”
[PDF 162KB] -
Mar 22, 2018
New Drug Application of Eldecalcitol, an Active Vitamin D3 Derivative, for the Treatment of Osteoporosis Accepted in China
[PDF 106KB] -
Mar 20, 2018
Long-Acting Erythropoiesis Stimulating Agent
“MIRCERA® Injection Syringe 12.5μg” Approved in Japan
[PDF 120KB] -
Mar 16, 2018
Chugai Decided as
2017 Tokyo Sports Promotion Model Company
[PDF 63KB] -
Mar 16, 2018
Chugai Starts Activities towards Commercialization of
Foundation Medicine’s Products in Japan
-- Chugai Enters a License Agreement with Roche and Submits for Regulatory Approval of “FoundationOne CDx™” -- [PDF 65KB] -
Feb 28, 2018
Chugai’s HEMLIBRA® Approved by European Commission in Hemophilia A with Inhibitors
- Approved in EU Following the US - [PDF 118KB] -
Feb 01, 2018
Organizational and Personnel Changes
[PDF 385KB] -
Feb 01, 2018
Notice of Distribution of Retained Earnings
[PDF 101KB] -
Feb 01, 2018
Notice Concerning the Difference Regarding Individual Financial Results as Compared to Actual Results for the Previous Year
[PDF 114KB] -
Feb 01, 2018
F. Hoffmann-La Roche Announces Financial Results for Fiscal 2017
[PDF 105KB] -
Feb 01, 2018
Further Improving Access to Therapies for Non-Small Cell Lung Cancer
Submitted Application for Partial Changes to Obtain an Additional Indication for “VENTANA OptiView ALK (D5F3)” as a Companion Diagnostic for ALK Inhibitor “Alecensa (alectinib)” [PDF 65KB] -
Jan 29, 2018
Chugai's HEMLIBRA® Gains Positive CHMP Opinion
in Hemophilia A with Inhibitors
[PDF 118KB] -
Jan 19, 2018
Chugai Obtains Approval of Humanized Anti-PD-L1 Monoclonal Antibody, “TECENTRIQ® Intravenous Infusion 1200mg” for the Treatment of Unresectable, Advanced or Recurrent Non-small Cell Lung Cancer
[PDF 107KB] -
Jan 09, 2018
Filing of Patent Infringement Lawsuit Concerning Rituxan® Injection, and a Petition for Provisional Disposition Order
[PDF 67KB] -
Jan 05, 2018
Notice Concerning Execution of Asset Transfer of 13 Long-Term Listed Products from Chugai to Taiyo Pharma
[PDF 112KB]
